Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
CUMBERLAND PHARMACEUTICALS INC roe for the quarter ending 2026-06-30 was -63.83%, a change of -53.24% year-over-year.
CUMBERLAND PHARMACEUTICALS INC roe for the quarter ending 2026-03-31 was -34.66%, a change of -23.10% year-over-year.
CUMBERLAND PHARMACEUTICALS INC roe for the quarter ending 2025-12-31 was -11.56%, a change of 17.19% year-over-year.
CUMBERLAND PHARMACEUTICALS INC roe for the quarter ending 2025-09-30 was -12.90%, a change of 31.52% year-over-year.
CUMBERLAND PHARMACEUTICALS INC roe for fiscal 2025 was -11.56%, a change of 17.19% from fiscal 2024.
CUMBERLAND PHARMACEUTICALS INC roe for fiscal 2024 was -28.74%, a change of -7.28% from fiscal 2023.
CUMBERLAND PHARMACEUTICALS INC roe for fiscal 2023 was -21.46%, a change of -5.98% from fiscal 2022.
CUMBERLAND PHARMACEUTICALS INC roe for fiscal 2022 was -15.48%, a change of -7.25% from fiscal 2021.